| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total other income, net | 10,153 | 8,741 | 6,478 | 9,058 |
| Net loss | -101,324 | -101,255 | -114,329 | -135,712 |
| Unrealized gain on marketable securities | 337 | -404 | 452 | 4,452 |
| Comprehensive loss | -100,987 | -101,659 | -113,877 | -131,260 |
| Net loss per share, basic | -0.92 | -0.98 | -1.1 | -1.34 |
| Net loss per share, diluted | -0.92 | -0.98 | -1.1 | -1.34 |
| Weighted average shares outstanding, basic | 110,188,000 | 103,732,000 | 103,500,000 | 101,002,000 |
| Weighted average shares outstanding, diluted | 110,188,000 | 103,732,000 | 103,500,000 | 101,002,000 |
Intellia Therapeutics, Inc. (NTLA)
Intellia Therapeutics, Inc. (NTLA)